文献速递痛风与晶体性关节病

痛风与已接种疫苗人群中严重SARS-CoV-2感染的超额风险:一项普通人群研究

Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study.
PubMed 文献 · Arthritis Rheumatol · 2022-11-30

该研究利用英国健康改善网络开展两项队列研究,随访2020年12月8日至2021年10月31日,比较痛风与非痛风人群的SARS-CoV-2感染及严重结局风险。接种疫苗队列中,痛风患者突破性感染风险升高(部分校正HR 1.24,95%CI 1.19-1.30),住院风险升高(校正HR 1.30,95%CI 1.10-1.53),死亡风险未达统计学显著(校正HR 1.36,95%CI 0.87-2.13)。女性痛风患者住院和死亡风险更高。

要点

  • 接种疫苗的痛风患者突破性感染风险升高(部分校正HR 1.24,95%CI 1.19-1.30)。
  • 痛风患者住院风险升高(校正HR 1.30,95%CI 1.10-1.53),死亡风险未达统计学显著(校正HR 1.36,95%CI 0.87-2.13)。
  • 女性痛风患者住院(校正HR 1.55,95%CI 1.15-2.10)和死亡(校正HR 2.46,95%CI 1.12-5.41)风险升高。

核心结论

  • 普通人群数据提示,痛风患者尤其女性,即使接种疫苗,仍有较高的SARS-CoV-2感染和严重结局风险。

研究设计与样本

  • 利用英国健康改善网络开展两项队列研究,比较痛风与非痛风普通人群,随访2020年12月8日至2021年10月31日。
  • 采用Cox比例风险模型按SARS-CoV-2疫苗接种状态估计率差(RD)和风险比(HR),并使用暴露评分重叠加权校正潜在混杂因素。

主要发现

  • 接种疫苗队列中,痛风组54,576人发生1,955例突破性COVID-19感染(4.68例/1000人月),非痛风组1,336,377人发生52,468例(3.76例/1000人月)。
  • 突破性感染部分校正RD为0.91例/1000人月(95%CI 0.62-1.20例/1000人月),部分校正HR为1.24(95%CI 1.19-1.30)。
  • 痛风与住院风险升高相关(校正HR 1.30,95%CI 1.10-1.53),死亡风险未达统计学显著(校正HR 1.36,95%CI 0.87-2.13)。
  • 女性痛风患者住院风险升高(校正HR 1.55,95%CI 1.15-2.10),死亡风险升高(校正HR 2.46,95%CI 1.12-5.41)。
  • 未接种疫苗队列中观察到与痛风相似的关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gout patients often have multiple comorbidities, making them susceptible to SARS-CoV-2 infection and poor outcomes. This study was undertaken to examine the association between gout and the risk of SARS-CoV-2 infection and severe outcomes, especially in patients who have received a SARS-CoV-2 vaccine. METHODS: We conducted 2 cohort studies using The Health Improvement Network in the UK. Individuals with gout and those without gout from the general population were followed up from December 8, 2020 to October 31, 2021. We estimated the rate difference (RD) and hazard ratio (HR) of SARS-CoV-2 infection and severe outcomes (i.e., hospitalization and death within 30 days after SARS-CoV-2 infection) for individuals with gout versus those without gout using a Cox proportional hazards model according to SARS-CoV-2 vaccination status. We adjusted for potential confounders by using overlap weighting of exposure scores. RESULTS: Among the vaccinated cohort, 1,955 cases of breakthrough COVID-19 infection occurred in 54,576 individuals with gout (4.68 cases per 1,000 person-months), and 52,468 cases occurred in 1,336,377 individuals without gout (3.76 cases per 1,000 person-months). The partially adjusted RD of breakthrough infection was 0.91 cases per 1,000 person-months (95% confidence interval [95% CI] 0.62-1.20 cases per 1,000 person-months), and the partially adjusted HR was 1.24 (95% CI 1.19-1.30). Gout was also associated with an increased risk of hospitalization (adjusted HR 1.30 [95% CI 1.10-1.53]) and death (adjusted HR 1.36 [95% CI 0.87-2.13]). Women with gout had an increased risk of hospitalization (adjusted HR 1.55 [95% CI 1.15-2.10]) and death (adjusted HR 2.46 [95% CI 1.12-5.41]). Similar associations with gout were observed in the unvaccinated cohort. CONCLUSION: These general population data suggest that individuals with gout, especially women, have higher risks of SARS-CoV-2 infection and severe outcomes, even when vaccinated.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Xie D, Choi HK, Dalbeth N, et al. Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. Arthritis Rheumatol. 2022. PMID: 36082457. doi:10.1002/art.42339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。